neuromuscular disorder News
-
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences ("atai" or the "Company"), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to developing interventions to improve various mental health disorders and induce behavioural changes through brain computer interface (BCI)-enabled ...
-
MDA Venture Philanthropy Grant to Support Development of ALS Biomarkers
The Muscular Dystrophy Association is pleased to announce the award of an MDA Venture Philanthropy (MVP) grant totaling $233,200 to Scottsdale, Ariz.-based Iron Horse Diagnostics to support development of a prognostic test for ALS (amyotrophic lateral sclerosis). Such a test could help improve and accelerate clinical trials and speed the development of life-saving drugs to people with ALS. MVP ...
By nVector
-
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla
Global pharma major, Lupin Limited (Lupin) announced today that it hasentered into a distribution agreement with Medis for Lupin’sorphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries.NaMuscla® is the first and only licensed ...
-
The First-in-Human Phase 1b Safety Clinical Trial of CuraVac’s Potential Myasthenia Gravis Therapeutic Vaccine Succesfully Meets its Safety Primary End Points.
General information: First-in-human clinical trial (phase 1b, I/II) testing the potential MG therapeutic vaccine, CV-MG01, against a placebo in patients with Myasthenia Gravis conducted at Antwerp University Hospital (UZA) in Belgium. The study consisted in 10 visits over 20 weeks (Part A) and is followed by a 2-year long term follow-up period (Part B-ongoing). Three cohorts of 8 patients were ...
-
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the “Disease models and Clinical Applications: ...
-
Chemical widely used in antibacterial hand soaps may impair muscle function
Triclosan, an antibacterial chemical widely used in hand soaps and other personal-care products, hinders muscle contractions at a cellular level, slows swimming in fish and reduces muscular strength in mice, according to researchers at the University of California, Davis, and the University of Colorado. The findings appear online in the Proceedings of the National Academy of Sciences of the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you